SOPHiA GENETICS Launches Proposed Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Source: PRnewswire
- Public Offering Announcement: SOPHiA GENETICS has announced the commencement of a proposed public offering, with plans to grant underwriters an option to purchase an additional 15% of ordinary shares, indicating the company's proactive approach to capital markets.
- Underwriter Selection: TD Cowen is acting as the lead underwriter for the offering, reflecting the company's strategic choice in financing to enhance financial flexibility for future growth initiatives.
- Market Condition Impact: The completion of the offering is subject to market and other conditions, indicating the company's pursuit of capital support amidst an uncertain market environment, which may affect short-term stock performance.
- Compliance Statement: The company emphasizes that the offering does not constitute a public sale in Switzerland, ensuring adherence to local financial services regulations, demonstrating its commitment to legal compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOPH
Wall Street analysts forecast SOPH stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.440
Low
7.00
Averages
7.00
High
7.00
Current: 5.440
Low
7.00
Averages
7.00
High
7.00
About SOPH
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOPHiA GENETICS Shareholders Approve All Proposals
- Board Elections: At the 2026 Annual General Meeting, 99.79% of shareholders voted to elect co-founder Dr. Jurgi Camblong as Executive Chairman of the Board, marking a significant governance shift aimed at strengthening leadership and guiding the company's strategic direction.
- New CEO Appointment: Ross Muken was elected as a new Board member with 99.88% support and will officially assume the role of Chief Executive Officer on July 1, 2026, indicating the company's ongoing evolution and innovation in the AI-driven precision medicine sector.
- Compensation Plan Approval: Shareholders approved the maximum compensation for the Board and Executive Committee, ensuring that the incentive structures for the 2026 fiscal year align with market competitiveness, which is crucial for attracting and retaining key talent to support future growth.
- Amendment to Articles: Shareholders approved an amendment to Article 4b of the Articles of Association to align with the annual share replenishment under the 2021 Equity Incentive Plan, which will help maintain consistency in future financing and shareholder interests.
See More
SOPHiA GENETICS Shareholders Approve All Proposals
- Board Elections: At the 2026 Annual General Meeting, shareholders elected Dr. Jurgi Camblong as Executive Chairman with 99.79% of votes and Ross Muken as a new Board member with 99.88%, marking a significant governance shift for the company.
- CEO Appointment: Ross Muken will officially assume the role of Chief Executive Officer on July 1, 2026, which is expected to drive further advancements in the AI-driven precision medicine sector, enhancing the company's competitive edge.
- Compensation Approval: Shareholders approved the maximum compensation packages for the Board and Executive Committee, ensuring the company can attract and retain key talent over the next year, thereby supporting the achievement of its long-term strategic goals.
- Governance Structure Enhancement: In light of the new Chairman's election, the Board introduced a Lead Independent Director role, ensuring transparency and effectiveness in governance, which lays a solid foundation for future growth.
See More
SOPHiA GENETICS Closes $57 Million Public Offering
- Successful Offering: SOPHiA GENETICS successfully closed its $57 million public offering announced on June 16, indicating strong market demand as the offering was oversubscribed, thereby enhancing the company's financing capabilities in the biotech sector.
- Share Issuance Details: A total of 12,104,900 ordinary shares were issued at an offering price of $4.75 per share, with underwriters fully exercising their option to purchase an additional 1,578,900 shares, reflecting investor confidence in the company's future growth.
- Market Performance: SOPH closed at $5.46 on Thursday, marking a 4.20% increase, while shares traded at $5.44 in the overnight market, down 0.37%, indicating some volatility in market sentiment.
- Underwriter Lineup: TD Cowen acted as the lead book-running manager for the offering, with Guggenheim Securities, BTIG, and Craig-Hallum serving as co-managers, showcasing a robust support network for the company in capital markets.
See More
SOPHiA GENETICS Closes $57.5 Million Public Offering
- Significant Fundraising: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, exceeding expectations and demonstrating strong investor demand, which is expected to bolster the company's capital base for future R&D and market expansion.
- Share Issuance Details: A total of 12,104,900 ordinary shares were sold at a public price of $4.75 per share, including 1,578,900 shares purchased through the underwriters' full exercise of their option, enhancing the company's liquidity and market recognition.
- Underwriter Performance: TD Cowen acted as the lead underwriter, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring the successful execution of the fundraising, reflecting market confidence in the company's prospects.
- Compliance and Transparency: The company filed a registration statement with the SEC, which was declared effective on August 15, 2025, ensuring compliance with securities laws and enhancing investor trust.
See More
SOPHiA GENETICS Closes $57.5 Million Public Offering Amid Strong Demand
- Fundraising Amount: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, reflecting strong investor demand as the offering was oversubscribed, leading underwriters to fully exercise their option for an additional 1,578,900 shares.
- Share Issuance Details: The company sold 12,104,900 ordinary shares at a public price of $4.75 per share, which included the additional shares from the underwriters' exercised option, thereby strengthening its capital base.
- Underwriter Lineup: TD Cowen acted as the lead underwriter for the offering, with Guggenheim Securities as the book-running manager, and BTIG and Craig-Hallum serving as lead managers, indicating strong market confidence in the company.
- Compliance Statement: The offering complies with the registration requirements of the Securities Act of 1933 and will not be publicly sold in Switzerland, ensuring regulatory compliance and investor protection.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Public Offering Pricing: SOPHiA GENETICS has announced the pricing of 6,508,650 ordinary shares at $4.75 each, with gross proceeds estimated at $50 million, demonstrating the company's ability to raise capital in the market.
- Underwriter Selection: The lead book-running manager for this offering is TD Cowen, indicating the company's focus on professionalism and market influence in its choice of underwriters, aimed at boosting investor confidence.
- Additional Purchase Option: The company is also granting underwriters a 30-day option to purchase up to 10,526,000 ordinary shares at the same price, a strategy that could further enhance market liquidity and investor interest.
- Market Reaction: Following the announcement, SOPH's stock price fell by 1.60% to $4.93, reflecting a cautious market sentiment regarding the offering, which may impact future investor attitudes.
See More
SOPHiA GENETICS Shareholders Approve All Proposals
- Board Elections: At the 2026 Annual General Meeting, 99.79% of shareholders voted to elect co-founder Dr. Jurgi Camblong as Executive Chairman of the Board, marking a significant governance shift aimed at strengthening leadership and guiding the company's strategic direction.
- New CEO Appointment: Ross Muken was elected as a new Board member with 99.88% support and will officially assume the role of Chief Executive Officer on July 1, 2026, indicating the company's ongoing evolution and innovation in the AI-driven precision medicine sector.
- Compensation Plan Approval: Shareholders approved the maximum compensation for the Board and Executive Committee, ensuring that the incentive structures for the 2026 fiscal year align with market competitiveness, which is crucial for attracting and retaining key talent to support future growth.
- Amendment to Articles: Shareholders approved an amendment to Article 4b of the Articles of Association to align with the annual share replenishment under the 2021 Equity Incentive Plan, which will help maintain consistency in future financing and shareholder interests.
See More
SOPHiA GENETICS Shareholders Approve All Proposals
- Board Elections: At the 2026 Annual General Meeting, shareholders elected Dr. Jurgi Camblong as Executive Chairman with 99.79% of votes and Ross Muken as a new Board member with 99.88%, marking a significant governance shift for the company.
- CEO Appointment: Ross Muken will officially assume the role of Chief Executive Officer on July 1, 2026, which is expected to drive further advancements in the AI-driven precision medicine sector, enhancing the company's competitive edge.
- Compensation Approval: Shareholders approved the maximum compensation packages for the Board and Executive Committee, ensuring the company can attract and retain key talent over the next year, thereby supporting the achievement of its long-term strategic goals.
- Governance Structure Enhancement: In light of the new Chairman's election, the Board introduced a Lead Independent Director role, ensuring transparency and effectiveness in governance, which lays a solid foundation for future growth.
See More
SOPHiA GENETICS Closes $57 Million Public Offering
- Successful Offering: SOPHiA GENETICS successfully closed its $57 million public offering announced on June 16, indicating strong market demand as the offering was oversubscribed, thereby enhancing the company's financing capabilities in the biotech sector.
- Share Issuance Details: A total of 12,104,900 ordinary shares were issued at an offering price of $4.75 per share, with underwriters fully exercising their option to purchase an additional 1,578,900 shares, reflecting investor confidence in the company's future growth.
- Market Performance: SOPH closed at $5.46 on Thursday, marking a 4.20% increase, while shares traded at $5.44 in the overnight market, down 0.37%, indicating some volatility in market sentiment.
- Underwriter Lineup: TD Cowen acted as the lead book-running manager for the offering, with Guggenheim Securities, BTIG, and Craig-Hallum serving as co-managers, showcasing a robust support network for the company in capital markets.
See More
SOPHiA GENETICS Closes $57.5 Million Public Offering
- Significant Fundraising: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, exceeding expectations and demonstrating strong investor demand, which is expected to bolster the company's capital base for future R&D and market expansion.
- Share Issuance Details: A total of 12,104,900 ordinary shares were sold at a public price of $4.75 per share, including 1,578,900 shares purchased through the underwriters' full exercise of their option, enhancing the company's liquidity and market recognition.
- Underwriter Performance: TD Cowen acted as the lead underwriter, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring the successful execution of the fundraising, reflecting market confidence in the company's prospects.
- Compliance and Transparency: The company filed a registration statement with the SEC, which was declared effective on August 15, 2025, ensuring compliance with securities laws and enhancing investor trust.
See More
SOPHiA GENETICS Closes $57.5 Million Public Offering Amid Strong Demand
- Fundraising Amount: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, reflecting strong investor demand as the offering was oversubscribed, leading underwriters to fully exercise their option for an additional 1,578,900 shares.
- Share Issuance Details: The company sold 12,104,900 ordinary shares at a public price of $4.75 per share, which included the additional shares from the underwriters' exercised option, thereby strengthening its capital base.
- Underwriter Lineup: TD Cowen acted as the lead underwriter for the offering, with Guggenheim Securities as the book-running manager, and BTIG and Craig-Hallum serving as lead managers, indicating strong market confidence in the company.
- Compliance Statement: The offering complies with the registration requirements of the Securities Act of 1933 and will not be publicly sold in Switzerland, ensuring regulatory compliance and investor protection.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Public Offering Pricing: SOPHiA GENETICS has announced the pricing of 6,508,650 ordinary shares at $4.75 each, with gross proceeds estimated at $50 million, demonstrating the company's ability to raise capital in the market.
- Underwriter Selection: The lead book-running manager for this offering is TD Cowen, indicating the company's focus on professionalism and market influence in its choice of underwriters, aimed at boosting investor confidence.
- Additional Purchase Option: The company is also granting underwriters a 30-day option to purchase up to 10,526,000 ordinary shares at the same price, a strategy that could further enhance market liquidity and investor interest.
- Market Reaction: Following the announcement, SOPH's stock price fell by 1.60% to $4.93, reflecting a cautious market sentiment regarding the offering, which may impact future investor attitudes.
See More
